Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma [Phase 2]

View source ↗

Summary

Atezolizumab (Tecentriq) was studied in a Phase 2 trial for efficacy and safety in previously treated advanced thymic carcinoma. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoma

Drugs mentioned

• Tecentriq (atezolizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Carcinoma, Thymic | Phase 2 | Status: COMPLETED